Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › CLRB

Cellectar Biosciences

CLRB Lead: Phase 2 ★ Read the deep dive → 2 Biotech Distilled articles ↓ 25 filings & releases ↓ Cash $34.0M (Jun 30, 2026) ↓ 2 verdicts ↓ 1 timing quote ↓
Oncology Radioligand

Market cap $11.8M 9.5M shares (10-Q, Aug 11, 2026) × $1.25 close Nov 6, 2026

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. FinancingLate 2026 / early 2027Financing, Late 2026 / early 2027, routine
  2. Iopofosine I 131 Ph3 startEarly 2027Iopofosine I 131 Ph3 start, Early 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

PDC

Phospholipid Drug Conjugate (PDC) delivery platform engineered to target and gain intracellular access to primary tumors, metastatic sites, and cancer stem cells; can be conjugated with small-molecule chemotherapeutics, radiotherapeutics, and other therapeutic molecules; focus areas include hematologic cancers and solid tumors

Phospholipid Drug Conjugate

PDC delivery platform designed to provide targeted delivery of radioisotopes and chemotherapeutics to cancer cells with improved efficacy and reduced off-target effects; applied across multiple oncology indications including hematologic malignancies and solid tumors

Discontinued (3)

Capital (as filed)

Cash
$34.0M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$6.0M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$34.0M cash, runway second quarter of 2027 per the update of Aug 13, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Cellectar Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-07 Watch Cellectar Biosciences (CLRB) - Scientific Deep Dive for Iopofosine and Pipeline Products Science is compelling and bankruptcy risk is removed, but the complex warrant overhang and Phase 3 execution risk warrant patience before sizing up.
  2. 2026-08-14 Watch UPDATE: Cellectar Biosciences (CLRB) - The Warrants Went Live WATCH maintained with downgraded urgency as 39.6M warrants at $2.65 are now exercisable creating a structural ceiling, NDA slipped to mid-2027, and another financing raise is likely before the key catalyst.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 1, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)